Covaxin SRP

## Report on Amendment to COVAXIN Prescribing Information **1. Executive Summary:** This report analyzes a directive from the Central Drugs Standard Control Organization (CDSCO), Biological Division, Government of India, regarding the COVAXIN vaccine. This directive serves as an amendment, instructing Bharat Biotech International Limited to update the Summary of Product Characteristics (SmPC), specifically Section 4.8, to include "Guillain-Barr Syndrome (GBS)" as a rare, potential adverse event following vaccination. The core purpose of this amendment is to provide updated safety information to healthcare professionals and patients regarding COVAXIN. The key finding is that the Signal Review Panel (SRP) has recommended this update based on AEFI (Adverse Events Following Immunization) data and published medical literature. **2. Introduction:** This report provides an overview of an amendment to the prescribing information for COVAXIN, as communicated in a letter from the Central Drugs Standard Control Organization (CDSCO) to Bharat Biotech International Limited. This analysis is based solely on the provided text of the letter. **3. Policy Overview:** This report concerns an *amendment* to the prescribing information for COVAXIN. * **Core Objective(s):** Based on the text, the primary objective is to update the prescribing information (SmPC) for COVAXIN to reflect the potential risk of Guillain-Barr Syndrome (GBS) following vaccination, based on the evaluation of AEFI data and published medical literature. This aims to provide more complete and accurate safety information to healthcare providers. **4. Background and Rationale:** This amendment arises from the evaluation of AEFI data and published medical literature by the Signal Review Panel (SRP). The SRP identified a potential association between COVAXIN vaccination and the occurrence of Guillain-Barr Syndrome (GBS). The amendment seeks to address the need for updated safety information for healthcare professionals administering COVAXIN and patients receiving it, likely due to increasing data about AEFI. **5. Key Provisions / Changes:** This section details the changes introduced by the amendment: * **Specific Part of Original Policy Being Changed:** Section '4.8 Undesirable effects of SmPC' of the COVAXIN Summary of Product Characteristics (SmPC). * **New Rule/Provision:** Inclusion of "Unknown frequency: GuillainBarr Syndrome GBS following vaccination with COVAXIN" in Section 4.8 of the SmPC. * **Difference/Effect of Change:** The amendment adds GBS as a potential adverse event to the list of known side effects. It changes the risk profile information available to healthcare providers and patients, allowing for better informed decision-making regarding COVAXIN vaccination and potentially improving early detection and management of GBS cases following vaccination. **6. Target Audience and Stakeholders:** The primary target audience is **Bharat Biotech International Limited**, who are directly instructed to update the SmPC. Other stakeholders include: * **Healthcare professionals:** Who prescribe and administer COVAXIN. * **Patients:** Receiving the COVAXIN vaccine. * **CDSCO**: As the regulatory agency responsible for overseeing drug safety. **7. Implementation Aspects (Inferred):** * **Responsible agency/bodies:** * **Bharat Biotech International Limited:** Responsible for updating the SmPC and submitting it to the Directorate. * **Signal Review Panel (SRP):** Responsible for evaluating data and recommending the inclusion of GBS in the SmPC. * **CDSCO's Biological Division:** Responsible for issuing the directive and overseeing the implementation. * **Timelines or procedures:** The text implies a need for prompt action by Bharat Biotech to update the SmPC and submit it to the Directorate. However, specific timelines are not mentioned in the text. The submission to the Directorate suggests an approval process. * **Implementation related specifically to changes:** Implementation requires Bharat Biotech to revise the Section 4.8 Undesirable effects of SmPC of COVAXIN's prescribing information to include GBS, and then submit the updated documentation to CDSCO. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this amendment is to enhance the transparency and completeness of safety information regarding COVAXIN. This update will inform healthcare professionals and patients about the potential risk of GBS following vaccination, allowing for more informed decisions and potentially improving the detection and management of GBS cases post-vaccination. It is expected to improve vaccine safety surveillance and awareness. **9. Conclusion:** The directive from the CDSCO represents an important amendment to the prescribing information for COVAXIN, reflecting the ongoing monitoring of vaccine safety and the commitment to providing updated information to healthcare professionals and patients. The inclusion of GBS as a rare, potential adverse event strengthens the safety profile transparency of COVAXIN and underscores the importance of continuous monitoring and evaluation of vaccine safety data. This amendment is significant because it directly impacts the information available to those making decisions about COVAXIN vaccination and necessitates immediate action by Bharat Biotech to comply with the regulatory directive.

Key Entities Referenced